Last reviewed · How we verify
Lentiviral G1XCGD Gene Therapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy) — University of California, Los Angeles.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lentiviral G1XCGD Gene Therapy TARGET | Lentiviral G1XCGD Gene Therapy | University of California, Los Angeles | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lentiviral G1XCGD Gene Therapy CI watch — RSS
- Lentiviral G1XCGD Gene Therapy CI watch — Atom
- Lentiviral G1XCGD Gene Therapy CI watch — JSON
- Lentiviral G1XCGD Gene Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Lentiviral G1XCGD Gene Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/lentiviral-g1xcgd-gene-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab